Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03090100




Registration number
NCT03090100
Ethics application status
Date submitted
22/03/2017
Date registered
24/03/2017
Date last updated
1/10/2019

Titles & IDs
Public title
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Secondary ID [1] 0 0
2016-002995-29
Secondary ID [2] 0 0
CR108278
Universal Trial Number (UTN)
Trial acronym
ECLIPSE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab
Treatment: Drugs - Placebo
Treatment: Drugs - Secukinumab

Experimental: Group I: Guselkumab Plus Placebo - Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.

Active comparator: Group II: Secukinumab - Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.


Treatment: Drugs: Guselkumab
Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.

Treatment: Drugs: Placebo
Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.

Treatment: Drugs: Secukinumab
Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48
Timepoint [1] 0 0
Week 48
Secondary outcome [1] 0 0
Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48
Timepoint [1] 0 0
Week 12 and 48
Secondary outcome [2] 0 0
Percentage of Participants Who Achieved a PASI-90 Response at Week 12
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Percentage of Participants Who Achieved a PASI-75 Response at Week 12
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Percentage of Participants Who Achieved a PASI-100 Response at Week 48
Timepoint [4] 0 0
Week 48
Secondary outcome [5] 0 0
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48
Timepoint [5] 0 0
Week 48
Secondary outcome [6] 0 0
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48
Timepoint [6] 0 0
Week 48
Secondary outcome [7] 0 0
Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48
Timepoint [7] 0 0
Week 16 and 48
Secondary outcome [8] 0 0
Percentage of Participants Who Achieved a PASI-75 Response at Week 16
Timepoint [8] 0 0
Week 16
Secondary outcome [9] 0 0
Percentage of Participants Who Achieved a PASI-90 Response at Week 16
Timepoint [9] 0 0
Week 16
Secondary outcome [10] 0 0
Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48
Timepoint [10] 0 0
Week 24 up to Week 48
Secondary outcome [11] 0 0
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16
Timepoint [11] 0 0
Week 16
Secondary outcome [12] 0 0
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12
Timepoint [12] 0 0
Week 12
Secondary outcome [13] 0 0
Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12
Timepoint [13] 0 0
Week 48
Secondary outcome [14] 0 0
Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16
Timepoint [14] 0 0
Week 48
Secondary outcome [15] 0 0
Percentage of Participants Who Achieved PASI Response (PASI 100, PASI-90, PASI-75 and PASI-50) Over Time From Week 1 to Week 56
Timepoint [15] 0 0
Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56
Secondary outcome [16] 0 0
Percentage of Participants With IGA Responses Through Week 56
Timepoint [16] 0 0
Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56
Secondary outcome [17] 0 0
Percent Improvement From Baseline in PASI Through Week 56
Timepoint [17] 0 0
Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and Week 56

Eligibility
Key inclusion criteria
* Have a diagnosis of plaque-type psoriasis (with or without [Psoriatic Arthritis]PsA) for at least 6 months before the first administration of study drug
* A woman of childbearing potential must have a negative urine pregnancy test at screening and at Week 0 and agree to urine pregnancy testing before receiving injections
* Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
* Agree not to receive a Bacille Calmette-Guérin (BCG) vaccination during the study, or within 12 months after the last administration of study drug
* Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* Has previously received guselkumab or secukinumab
* Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
* Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly
* Is unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/04/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/09/2018
Sample size
Target
Accrual to date
Final
1048
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Skin Centre - Benowa
Recruitment hospital [2] 0 0
Sinclair Dermatology - East Melbourne
Recruitment hospital [3] 0 0
Fremantle Dermatology - Fremantle
Recruitment hospital [4] 0 0
Clinical Trials SA Pty Ltd - Hectorville
Recruitment hospital [5] 0 0
Premier Specialists - Kogarah
Recruitment hospital [6] 0 0
St George Dermatology & Skin Cancer Centre - Kogarah
Recruitment hospital [7] 0 0
Skin&Cancer Foundation Inc - Melbourne
Recruitment hospital [8] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [9] 0 0
Westmead Hospital - Westmead
Recruitment hospital [10] 0 0
Woden Dermatology - Woden
Recruitment hospital [11] 0 0
Veracity Clinical Research - Woolloongabba
Recruitment postcode(s) [1] 0 0
4217 - Benowa
Recruitment postcode(s) [2] 0 0
3002 - East Melbourne
Recruitment postcode(s) [3] 0 0
6160 - Fremantle
Recruitment postcode(s) [4] 0 0
5073 - Hectorville
Recruitment postcode(s) [5] 0 0
2217 - Kogarah
Recruitment postcode(s) [6] 0 0
3053 - Melbourne
Recruitment postcode(s) [7] 0 0
3050 - Parkville
Recruitment postcode(s) [8] 0 0
2145 - Westmead
Recruitment postcode(s) [9] 0 0
2606 - Woden
Recruitment postcode(s) [10] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Rhode Island
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Ajax
Country [26] 0 0
Canada
State/province [26] 0 0
Edmonton
Country [27] 0 0
Canada
State/province [27] 0 0
Halifax
Country [28] 0 0
Canada
State/province [28] 0 0
Mississauga
Country [29] 0 0
Canada
State/province [29] 0 0
Montreal
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Canada
State/province [31] 0 0
Surrey
Country [32] 0 0
Canada
State/province [32] 0 0
Waterloo
Country [33] 0 0
Canada
State/province [33] 0 0
Windsor
Country [34] 0 0
Czechia
State/province [34] 0 0
Jihlava
Country [35] 0 0
Czechia
State/province [35] 0 0
Kutna Hora
Country [36] 0 0
Czechia
State/province [36] 0 0
Nachod
Country [37] 0 0
Czechia
State/province [37] 0 0
Novy Jicin
Country [38] 0 0
Czechia
State/province [38] 0 0
Ostrava- Poruba
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha
Country [40] 0 0
Czechia
State/province [40] 0 0
Svitavy
Country [41] 0 0
Czechia
State/province [41] 0 0
Usti Nad Labem
Country [42] 0 0
France
State/province [42] 0 0
Bordeaux
Country [43] 0 0
France
State/province [43] 0 0
Brest
Country [44] 0 0
France
State/province [44] 0 0
La Rochelle
Country [45] 0 0
France
State/province [45] 0 0
Martigues
Country [46] 0 0
France
State/province [46] 0 0
Nantes
Country [47] 0 0
France
State/province [47] 0 0
Nice
Country [48] 0 0
France
State/province [48] 0 0
Rouen
Country [49] 0 0
France
State/province [49] 0 0
Toulouse
Country [50] 0 0
Germany
State/province [50] 0 0
Berlin
Country [51] 0 0
Germany
State/province [51] 0 0
Bonn
Country [52] 0 0
Germany
State/province [52] 0 0
Dresden
Country [53] 0 0
Germany
State/province [53] 0 0
Essen
Country [54] 0 0
Germany
State/province [54] 0 0
Frankfurt am Main
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Kiel
Country [57] 0 0
Germany
State/province [57] 0 0
Luebeck
Country [58] 0 0
Germany
State/province [58] 0 0
Mahlow
Country [59] 0 0
Germany
State/province [59] 0 0
Muenchen
Country [60] 0 0
Germany
State/province [60] 0 0
Muenster
Country [61] 0 0
Germany
State/province [61] 0 0
Tuebingen
Country [62] 0 0
Germany
State/province [62] 0 0
Witten
Country [63] 0 0
Hungary
State/province [63] 0 0
Budapest
Country [64] 0 0
Hungary
State/province [64] 0 0
Debrecen
Country [65] 0 0
Hungary
State/province [65] 0 0
Kaposvar
Country [66] 0 0
Hungary
State/province [66] 0 0
Kecskemet
Country [67] 0 0
Hungary
State/province [67] 0 0
Miskolc
Country [68] 0 0
Hungary
State/province [68] 0 0
Pecs
Country [69] 0 0
Hungary
State/province [69] 0 0
Szeged
Country [70] 0 0
Hungary
State/province [70] 0 0
Szombathely
Country [71] 0 0
Hungary
State/province [71] 0 0
Veszprem
Country [72] 0 0
Poland
State/province [72] 0 0
Bialystok
Country [73] 0 0
Poland
State/province [73] 0 0
Bydgoszcz
Country [74] 0 0
Poland
State/province [74] 0 0
Elblag
Country [75] 0 0
Poland
State/province [75] 0 0
Gdansk
Country [76] 0 0
Poland
State/province [76] 0 0
Krakow
Country [77] 0 0
Poland
State/province [77] 0 0
Lodz
Country [78] 0 0
Poland
State/province [78] 0 0
Poznan
Country [79] 0 0
Poland
State/province [79] 0 0
Swidnik
Country [80] 0 0
Poland
State/province [80] 0 0
Torun
Country [81] 0 0
Poland
State/province [81] 0 0
Warszawa
Country [82] 0 0
Poland
State/province [82] 0 0
Wroclaw
Country [83] 0 0
Spain
State/province [83] 0 0
Alcorcon
Country [84] 0 0
Spain
State/province [84] 0 0
Alicante
Country [85] 0 0
Spain
State/province [85] 0 0
Badalona
Country [86] 0 0
Spain
State/province [86] 0 0
Barakaldo
Country [87] 0 0
Spain
State/province [87] 0 0
Barcelona
Country [88] 0 0
Spain
State/province [88] 0 0
Bilbao Vizcaya
Country [89] 0 0
Spain
State/province [89] 0 0
Cordoba
Country [90] 0 0
Spain
State/province [90] 0 0
Madrid
Country [91] 0 0
Spain
State/province [91] 0 0
Manises
Country [92] 0 0
Spain
State/province [92] 0 0
Pontevedra
Country [93] 0 0
Spain
State/province [93] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT03090100